Johnson & Johnson Share Price

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 01:30:02 14/06/2024 am IST 5-day change 1st Jan Change
145.4 USD +0.03% Intraday chart for Johnson & Johnson -0.66% -7.20%
Sales 2024 * 88.79B 7,416B Sales 2025 * 92.1B 7,694B Capitalization 350B 29,240B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.94 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.8 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 1,31,900
Yield 2024 *
3.32%
Yield 2025 *
3.46%
Free-Float 77.08%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.25%
1 week-0.66%
Current month-0.83%
1 month-3.82%
3 months-9.71%
6 months-6.64%
Current year-7.20%
More quotes
1 week
143.88
Extreme 143.88
147.56
1 month
143.71
Extreme 143.71
154.86
Current year
143.13
Extreme 143.13
163.58
1 year
143.13
Extreme 143.13
175.97
3 years
143.13
Extreme 143.13
186.69
5 years
109.16
Extreme 109.16
186.69
10 years
81.79
Extreme 81.79
186.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 01/89/01
Director of Finance/CFO 57 01/98/01
Chief Tech/Sci/R&D Officer 58 05/19/05
Members of the board TitleAgeSince
Director/Board Member 70 25/19/25
Director/Board Member 72 19/14/19
Director/Board Member 70 22/09/22
More insiders
Date Price Change Volume
13/24/13 145.4 +0.03% 6,840,166
12/24/12 145.4 -0.92% 6,180,493
11/24/11 146.8 -0.25% 5,661,236
10/24/10 147.1 +0.03% 5,751,309
07/24/07 147.1 +0.45% 5,111,626

Delayed Quote Nyse, June 14, 2024 at 01:30 am IST

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
145.4 USD
Average target price
171.7 USD
Spread / Average Target
+18.06%
Consensus